Header Logo

Connection

JOSEPH JANKOVIC to Randomized Controlled Trials as Topic

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Randomized Controlled Trials as Topic.
JOSEPH JANKOVIC
Connection Strength
0.930
Randomized Controlled Trials as Topic
  1. Botulinum Toxin for the Treatment of Tremors. Toxins (Basel). 2025 Aug 11; 17(8).
    View in: PubMed
    Score: 0.164
  2. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
    View in: PubMed
    Score: 0.154
  3. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 10; 17(4):1681-1693.
    View in: PubMed
    Score: 0.117
  4. Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017 Nov; 13(11):643-644.
    View in: PubMed
    Score: 0.095
  5. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
    View in: PubMed
    Score: 0.086
  6. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.084
  7. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):961-2; author reply 962-3.
    View in: PubMed
    Score: 0.057
  8. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008 Mar; 63(3):267-9.
    View in: PubMed
    Score: 0.049
  9. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul; 20(7):981-90.
    View in: PubMed
    Score: 0.038
  10. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.023
  11. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
    View in: PubMed
    Score: 0.020
  12. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013 Jun 01; 67:141-52.
    View in: PubMed
    Score: 0.017
  13. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
    View in: PubMed
    Score: 0.013
  14. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.